ArticleObesity (Silver Spring, Md.)2020
Per- and Polyfluoroalkyl Substance Exposure, Gestational Weight Gain, and Postpartum Weight Changes in Project Viva.
Article in Obesity (Silver Spring, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Per- and polyfluoroalkyl substances serum concentrations during pregnancy and gestational weight gain in the Healthy Start Study.International journal of hygiene and environmental health · 2026Article
- From Exposure to Dysfunction: The Intestinal Toxicity of Per- and Polyfluoroalkyl Substances.Toxics · 2025Review
- Maternal factors associated with plasma concentrations of endocrine-disrupting persistent organic pollutants including PFAS among Hispanic women from pregnancy to the post-delivery period.Environment international · 2025Article
- Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity.The Journal of clinical endocrinology and metabolism · 2025Article
- Early-pregnancy per- and polyfluoroalkyl substances and maternal post-pregnancy weight trajectory.Obesity (Silver Spring, Md.) · 2025Article
- Associations of maternal per- and polyfluoroalkyl substance plasma concentrations during pregnancy with offspring polycystic ovary syndrome and related characteristics in project viva.Environmental research · 2025Article
- Effect of Per and Poly-Fluoroalkyl Substances on Pregnancy and Child Development.Current pediatric reviews · 2025Review
- Maternal Serum Concentrations of Per- and Polyfluoroalkyl Substances and Gestational Weight Gain: A Systematic Review and Meta-analysis.International journal of preventive medicine · 2025Review
- Review
- Endocrine disrupting chemicals: gestational diabetes and beyond.Diabetology & metabolic syndrome · 2024Review
- Plasma concentrations of per- and polyfluoroalkyl substances in pregnancy and breastfeeding duration in Project Viva.The Science of the total environment · 2023Article
- Per- and polyfluoroalkyl substances, gestational weight gain, postpartum weight retention and body composition in the UPSIDE cohort.Environmental health : a global access science source · 2023Article
- Article
- C57BL/6J mice exposed to perfluorooctanoic acid demonstrate altered immune responses and increased seizures after Theiler's murine encephalomyelitis virus infection.Frontiers in immunology · 2023Article
- Evaluating maternal exposure to an environmental per and polyfluoroalkyl substances (PFAS) mixture during pregnancy: Adverse maternal and fetoplacental effects in a New Zealand White (NZW) rabbit model.The Science of the total environment · 2022Article
- Obesity II: Establishing causal links between chemical exposures and obesity.Biochemical pharmacology · 2022Review
- Imputation of Below Detection Limit Missing Data in Chemical Mixture Analysis with Bayesian Group Index Regression.International journal of environmental research and public health · 2022Article
- Maternal Levels of Perfluoroalkyl Substances (PFAS) during Early Pregnancy in Relation to Preeclampsia Subtypes and Biomarkers of Preeclampsia Risk.Environmental health perspectives · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThe purpose of this study was to test the extent to which pregnancy per- and polyfluoroalkyl substance (PFAS) concentrations were associated with gestational weight gain and postpartum weight changes.
methodsThis study was composed of 1,614 women recruited between 1999 and 2002 via the Project Viva cohort with pregnancy plasma concentrations of six PFAS, including perfluorooctanesulfonic acid, perfluorooctanoic acid (PFOA), and 2-(N-ethyl-perfluorooctane sulfonamido) acetic acid. Gestational weight gain was defined as the difference between last pregnancy weight and prepregnancy weight, 1-year postpartum weight retention as the difference between 1-year postpartum weight and prepregnancy weight, and 3-year postpartum weight change as the difference between 3-year postpartum weight and prepregnancy weight.
resultsDuring pregnancy, women gained 0.37 kg (95% CI: 0.11-0.62) more weight per doubling of 2-(N-ethyl-perfluorooctane sulfonamido) acetic acid. At 1 year post partum, women retained 0.55 kg (95% CI: 0.07-1.04) more weight per doubling of PFOA. At 3 years post partum, women gained 0.91 kg (95% CI: 0.25-1.56) more weight per doubling in PFOA. Findings were similar after adjustment for all PFAS. Other PFAS were not associated with weight changes. Postpartum associations were stronger among women with higher prepregnancy BMI. Models were adjusted for demographics.
conclusionsPregnancy PFAS were associated with greater gestational weight gain, weight retention, and weight gain years after pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.